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Analysis of microRNA (miRNA) biogenesis and function is an area of research that started only recently but has subsequently
accelerated tremendously. This is because of the impressive impact of miRNA-mediated gene regulation and the obvious potential
of those tiny RNA molecules in future diagnostic and therapeutic applications. In this review, recent progress to reveal the role
of miRNAs in the tumourigenesis of malignant melanoma, as well as future prospects of melanoma-related miRNA research, will
be addressed.
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MALIGNANT MELANOMA – FIGURES AND FACTS
Malignant melanoma is the most aggressive form of skin cancer
and according to the World Health Organization (WHO), the
number of melanoma cases worldwide is increasing faster than
that of any other type of cancer (Parkin et al, 2001). Recent
estimates suggest a doubling of melanoma incidence every 10–20
years (Garbe and Leiter, 2009). Melanoma accounts for only about
4% of skin cancer cases but for as many as 74% of all skin cancer
deaths. In 2002, the WHO estimated 160000 new cases of malig-
nant melanoma worldwide and reported 41000 deaths caused by
this dreadful disease (Parkin et al, 2005).
Although there is a good chance for the recovery of patients
suffering from melanoma if the primary lesion is detected very
early (more than 90% survival in stage I melanomas), prognosis of
5-year survival for more advanced melanomas drops down across
approximately 60% (stage II) of cases to as low as 10% (stage III)
or to even complete fatality (stage IV). This reflects the current
lack of therapeutic approaches for treating advanced melanoma.
Beyond an early surgical removal of the primary tumour after
diagnosis, there is currently no promising standard therapy avail-
able for the treatment of melanomas in more advanced stages. This
fact gets even more aggravating, considering metastasis to distinct
organs at a very early event in the progression of this disease.
Traditionally, five distinct steps of melanoma development and
progression are distinguished: A dysplastic nevus (2) showing a
high level of structural and architectural atypia arises from a
common acquired nevus (1). The subsequent radial growth phase
(RGP) primary melanoma (3) is the first recognisable malignant
stage in which cells do not possess metastatic potential but are
already locally invasive. RGP can be followed by VGP (vertical
growth phase) primary melanoma lesions (4) in which melanoma
cells infiltrate and invade the dermis and show metastatic potential.
This process finally results in metastasis to distant organs by an
overgrowth of disseminated tumour cells at these sites (5).
Enormous efforts are taken to unravel the molecular mecha-
nisms that lead to these observed changes in cell architecture
and cellular processes and the resulting malignant behaviour of
transformed melanocytes. One family of molecules involved in
the genesis and progression of melanoma cells, the microRNAs
(miRNAs), is now attracting a lot of attention.
MicroRNA – BIOGENESIS AND FUNCTION
MicroRNAs, a class of small non-coding RNAs, were first described
in Caenorhabditis elegans in the laboratory studies conducted
by Victor Ambros and Gary Ruvkun when they discovered lin-4
(Lee et al, 1993; Wightman et al, 1993).
It took until the year 2000, when the detection of a second
miRNA species – let-7 – by Reinhart et al (2000) and the finding
that the members of this miRNA family were conserved in a large
variety of Metazoens from Drosophila to humans (Pasquinelli
et al, 2000; Slack et al, 2000), to fuel miRNA research.
Subsequently, it seemed that this class of molecules regulates gene
expression on a posttranscriptional level in presumably every
multicellular organism.
MicroRNAs are encoded in the human genome as miRNA genes
composed of either a single miRNA species (monocistronic) or
several different miRNAs (polycistronic). In most cases, miRNA
genes are initially transcribed by RNA polymerase II, resulting in
capped and polyadenylated primary transcripts, called pri-miRs,
and usually several kilobases in length (for a detailed review on
miRNA biogenesis see (Filipowicz et al, 2008)). While still in the
nucleus, an approximately 60–110-nucleotide stem-loop structure
containing the mature miRNA sequence is cut out of the pri-miR
by the microprocessor complex, which is mainly composed of the
RNAse III enzyme Drosha and its co-factor DGCR8 (the human
homologue to Drosophila’s Pasha protein). The resulting pre-
miRNA (pre-miR) is rapidly translocated to the cytoplasm through
the Ran-GTP-dependent nuclear export factor, exportin-5. After a
second RNAse III enzyme known as Dicer (together with its co-
factor TRBP) excised an approximately 18–24-nucleotide double
strand from the pre-miR, the resulting RNA-duplex associates
with the miRNA-induced silencing complex (miRISC), the core of
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strand – the mature miRNA – remains stable on the RISC and
induces a posttranscriptional silencing of target genes by binding
with imperfect complementary to sequences in the 30UTRs of their
transcripts.
Until today, more than 650 miRNAs have been discovered in
the human genome (www.microRNA.org; Betel et al, 2008), and
these are estimated to regulate about 30% of all human tran-
scripts (Lewis et al, 2005). miRNAs are involved in the regula-
tion of multiple cellular processes, such as proliferation, apoptosis,
cell-cycle regulation, and differentiation. As a consequence, abnor-
malities in miRNA activity also contribute to the formation and
progression of cancer diseases (reviewed in Visone and Croce,
2009; Mirnezami et al, 2009).
ROLE OF miRNAs IN MELANOMA – SUMMARY OF
AVAILABLE DATA
A short history about miRNA expression profiling in
malignant melanoma
Initial data on miRNA expression in malignant melanoma samples
were included in an article published by Lu et al (2005). They
examined the expression of 217 mammalian miRNAs in as much
as 334 samples, most of them tumour tissues from several different
types of cancer (detailed presentation available at http://www.
broad.mit.edu). In their remarkable study, they were able to show
that miRNA expression profiles reflect the developmental lineage
and differentiation state of solid tumours. They also found that
poorly differentiated tumours can be successfully classified by
their miRNA expression profile in contrast to their mRNA profile.
Within the set of specimens were three melanoma tissue samples
and two melanoma cell lines. As the interest of Lu et al was focused
on other aspects, unfortunately no normal melanocyte samples
were examined. Thus, miRNAs differentially expressed in mela-
noma cells compared with the normal biological correlate cannot
be determined from their data sets.
During the next 2 years, information published about miRNA
expression in melanoma cells was further included only in studies
analysing large panels of tissues and cell lines derived from several
different types of cancer (Zhang et al, 2006; Gaur et al, 2007).
Zhang et al (2006) demonstrated in an extensive array CGH setup
that a large number of miRNAs are subject to DNA copy number
abnormalities in cancer. In the set of 227 human specimens that
they examined, 45 primary cultured melanoma cell lines (contri-
buted by Meenhard Herlyn) were included. Zhang et al showed
that 85.9% of genomic loci harbouring one or more of the 283
examined miRNA genes exhibited DNA copy number alterations
in melanoma and that some of these changes were specific to this
kind of cancer. They further confirmed a correlation of copy
number alterations and the expression of miRNAs located in this
region, indicating that copy number alterations of miRNA genes
may account partly for miRNA gene deregulation. It is noteworthy
to mention that the latter conclusion was drawn from experiments
carried out in ovarial cancer samples included in their study. In
general, Zhang et al, focused on breast and ovarian cancer samples
in their panel of tissues and cell lines. Besides, owing to the low
resolution of aCGH techniques, the identification of single miRNA
species amplified/lost in melanoma cells would have hardly been
possible in this experimental setup.
Gaur et al (2007) examined the expression of 241 mature miRNA
species in the 59 cell lines of the NCI-60 panel of human tumour-
derived cell lines, together with 13 corresponding normal tissues.
The NCI-60 panel comprises of cell lines derived from melanoma
as well as from cancers of the gastrointestinal tract, kidney, ovary,
breast, prostate, lung, central nervous system, and from different
leukaemia. They identified a set of 15 miRNAs that were expressed
significantly differently in the eight melanoma cell lines included
and which separated those from other cancer cell lines (4 up- and
11 downregulated miRNAs). Despite confirming that tumours can
be classified by their patterns of miRNA expression, Gaur et al, did
not characterise melanoma-specific miRNAs in depth. In contrast
to the cell lines from colon, haematological, and central nervous
system, a comparison of miRNA expression profiles of melanoma
cell lines with correlated healthy tissue was not carried out. A study
complementing the work by Gaur et al, on the NCI-60 cell lines
and additionally pointing towards a potential role of miRNAs in
chemoresistence was carried out by Blower et al (2007).
In January 2008, a review by Molnar et al (2008) was published,
in which they summarised data collected on changes in miRNA
expression in solid tumours and discussed them with regard to
melanoma. They underlined the potential of miRNA profiling to
identify miRNAs with a prognostic value in diagnosis and the
staging of malignant melanoma, as well as targets for new approaches
towards therapy of this disease. The first study carrying out a detailed
comparison of the miRnomes of normal human melanocytes to well-
characterised melanoma cell lines derived from primary tumours and
melanoma metastases was published in February 2009 (Mueller et al,
2009). In addition to melanocytes and melanoma cell lines, several
model systems used for investigating important steps in melanoma
development and progression were included in this work. The
experimental setup of this study made it possible to identify miRNAs
differentially expressed in each step of melanoma tumourigenesis,
such as early development and metastasis. The most important
findings can be summarised as follows: (i) expression of a high
number of miRNAs is deregulated in melanoma cells compared
with normal melanocytes, in which the bulk of miRNAs is
upregulated in melanoma cell lines. (ii) The bulk of miRNAs
deregulated most strongly was not described to be of importance
in tumour development before. (iii) Heterogeneity of melanoma
cells causes intrinsic changes in the expression of some miRNAs,
which makes it necessary to analyse sets of cell lines/tissue samples
to minimise the effects of individual alterations. Quality of data
obtained was checked by carrying out a qRT–PCR analysis on some
miRNAs deregulated most strongly or indicated to be involved in
the progression of other cancer diseases. The expression of those
miRNAs was also examined in a set of melanoma tissue samples
(most of them being laser microdissected) to ensure that the
observed deregulation also harbours relevance in vivo.I ti s
interesting to note that several miRNAs, proven to harbour
oncogenic or tumour-suppressive potential in other types of
tumours, were found to be deregulated in malignant melanoma
as well. Thus, these miRNAs may also be relevant in malignant
melanoma, although the mechanisms by which they exert their
function in this kind of cancer remain to be elucidated.
Information about miRNAs confirmed to be deregulated during
this study is included in Figure 1, which gives an overview about
single miRNA species demonstrated to be deregulated in
melanomagenesis.
Functional characterisation of single miRNA species in
melanoma cells
The first report linking the deregulated expression of a single
miRNA to its function in melanoma tumourigenesis was pub-
lished by Bemis et al (2008). It is not surprising that the ‘master
regulator’ of melanocyte cell growth, maturation, apoptosis, and
pigmentation – MITF – was the first gene determined as a target
for miRNA-mediated regulation in melanoma (Bemis et al, 2008).
Bemis et al, initially carried out a database search for miRNAs
located at the chromosomal region 1p22, a region known to
harbour changes related to melanoma susceptibility. MiR-137
was recognised to be encoded in this region, and computational
analysis showed MITF as a potential target gene for this miRNA.
Bemis et al, verified the suppression of MITF as a consequence of
miRNAs in melanoma
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noma cell lines expressing MITF show a larger number of a 15-base
pair variable number tandem repeat (VNTR) in the 50 UTR of
the miR-137 primary transcript. This amplified VNTR alters the
secondary structure of pri-miR-137 so that it cannot be processed
further and no mature miRNA can be generated. This observation
may explain the highly variable expression of MITF in melanoma
cells. Bemis et al, already suggested that there might be more
miRNAs regulating MITF, and they were right; recently, a paper
was published in PNAS that determined miR-182 to be a negative
regulator of MITF expression (Segura et al, 2009). Starting from a
chromosomal aberration (7q31–34, a genomic location frequently
amplified in melanoma and also harbouring c-MET and BRAF),
Segura et al, linked overexpression of miR-182 to increased
survival and invasive potential in melanoma cells by repressing
MITF and FOXO3 (a transcription factor of the Forkhead family).
Overexpression of miR-182 was unable to transform human
immortal melanocytes, but strongly stimulated the oncogenic
properties of established melanoma cells, especially their ability
for anchorage-independent growth and to move through the
extracellular matrix. In vivo experiments in a mouse model for
melanoma lung metastasis further confirmed a clear effect of
miR-182 on the ability of melanoma cells to build metastases in
distant organs. Considering the hypothesis that MITF has to be
upregulated in early melanoma development and subsequently
downregulated when the tumour becomes invasive, the interplay
between miR-137 and miR-182, and possibly some other miRNAs,
may have a key role in the MITF regulating network.
Further, miRNAs with known target genes in melanoma are
miR-221 and miR-222, which are clustered on the X chromosome
and transcribed as a common precursor. After being reported
to be overexpressed in a variety of cancers in which they exert
their function by repressing the c-Kit receptor, a group around
Alessandra Care ` found that both miRs are also directly involved
in melanoma pathogenesis (Felicetti et al, 2008b; Felicetti et al,
2008a). The rationale behind investigating miR-221/-222 was
straightforward, as the majority of invasive and metastatic
melanomas shows a downregulation of the c-Kit receptor. Felicetti
et al showed that this diminished expression of c-Kit is a result of
the upregulation of miR-221/-222 expression during melanoma
progression from primary tumour to a more invasive melanoma
phenotype. In addition, repression of p27, another miR-221/-222
target gene identified in prostate carcinoma and glioblastoma
studies, could be confirmed in melanoma cells. Overexpression of
miR-221/-222 in melanoma cells harbouring a low endogenous
level of both miRNAs led to increased proliferation (through
acceleration of the cell cycle), increased invasive and chemotactic
capabilities, and accelerated tumour growth in a mouse melanoma
model. Conversely, treatment of melanoma cells harbouring a high
level of miR-221/-222 with antagomiRs against both miRNAs
resulted in a reduced proliferation rate and a decrease in invasion
and migration abilities. It should be noted that tumour growth was
efficiently reduced when antagomiRs against miR-221/-222 were
injected directly into the tumour mass. Thus, it was shown that
miR-221/-222 regulates two divergent pathways leading to mela-
noma progression and that treatment with antagomiRs against
miR-221/-222 can inhibit melanoma progression in vitro as well
as in vivo. The enhanced expression of miR-221/-222 was shown
to be caused by a loss of the transcription factor PLZF in mela-
noma cells, as the latter binds to the miR-221/-222 promoter
and acts as a transcriptional repressor in normal melanocytes.
Similar results were obtained by Igoucheva and Alexeev (2009),
who interestingly revealed that c-Kit regulation is mainly based on
miRNA-dependent mechanisms and is independent of the AP-2
transcription factor.
The first miRNA verified to be actively involved in the formation
of cancers was miRNA let-7. Frank Slack’s group was able to link
the deregulated expression of let-7 in human cancer cells to initial
mechanisms of tumour development by the identification of one
of its main targets – Ras (Johnson et al, 2005). Research on the
let-7 family of miRNAs also revealed an important function of
its members in melanoma tumourigenesis. The group around
Manfred Kunz was able to show that let-7b both directly and
indirectly targets cell cycle regulators in melanoma (Schultz et al,
2008). Analysing 10 melanocytic nevi and 10 primary melanomas
for differentially expressed miRNAs, they revealed five members
of the let-7 family to be significantly downregulated in melanoma
cells. Further experiments with let-7b mimics showed a reduced
expression of cyclins A, D1, D3, and cyclin-dependent kinase
(Cdk) 4 in transfected melanoma cells. Schultz et al were able to
verify a direct interaction of let-7b with the cyclin D1 30UTR,
whereas at least some of the effects on other cyclins are likely to be
indirect. Nevertheless, a transfection of let-7b mimics was shown
to decelerate cell cycle in melanoma cells, reflected by a significant
reduction in the number of melanoma cells in the S-phase and an
increase in the number of cells in the G1 phase. The transfection of
artificial let-7b molecules into melanoma cells also diminished
their ability for anchorage-independent growth. These findings
assigned let-7b a role as an important negative regulator of
melanoma cell growth and proliferation through inhibition of
cell-cycle progression.
Another member of the let-7 family of miRNAs, namely, let-7a,
was demonstrated to regulate the expression of integrin beta3 by
a direct interaction with a binding site in its 30UTR (Muller and
Bosserhoff, 2008). It was further shown that the loss of let-7a
expression is the main regulatory mechanism leading to increased
integrin beta3 expression in melanoma cells, whereas promoter-
dependent mechanisms have only a minor role. Integrin beta3 is
highly related to melanoma progression and leads to enhanced
migratory and invasive potential of melanoma cells. In line with
these observations, transfection of let-7a mimics into melanoma
cells reduced their invasive potential by approximately 75%.
Treatment with let-7a anti-miRs, on the other hand, was sufficient
to induce migration of otherwise normal melanocytes. These
findings revealed that let-7a exerts a strong impact on melanoma
tumourigenesis by regulating target genes involved in different
cellular mechanisms, contributing to the progression of melanoma
cells. On the one hand, expression of the Ras oncogene is regulated
by let-7a in melanoma (as well as in other types of cancer). The
loss of let-7a thereby leads to enhanced cell proliferation. On the
other hand, let-7a is the basic mechanism for the regulation of
integrin beta3 expression; thus, migration and invasion of mela-
noma cells is enhanced by depletion of let-7a.
The known miRNA:target interactions in melanoma and their
implications in main cellular processes identified in the course of
the studies cited in this paragraph are presented in Figure 2.
Normal Primary tumour Metastasis
miR-182, miR-137, miR-221/-222, (miR-17-5p), (mir-373)
let-7a, let7b, (miR-181a), (miR-194)
Figure 1 Schematic representation of microRNAs (miRNAs) demon-
strated to be up- or downregulated during tumourigenesis of malignant
melanoma, as described in the paragraph ‘Functional characterisation of
single miRNA species in melanoma cells’. miRNAs shown to be deregulated
in melanoma progression by a microarray study (Mueller et al, 2009) and
subsequently confirmed by qRT–PCR as described in the paragraph
‘A short history about miRNA expression profiling in malignant melanoma’ are
indicated by parenthesis.
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malignant melanoma
Ozsolak et al (2008) identified promoter regions of 175 human
miRNAs by combining nucleosome mapping with chromatin
signatures for promoters. Besides several findings of utmost
importance for general miRNA research, they were able to deter-
mine nine miRNAs (e.g., miR-146a, miR-221/222, and miR-363)
that are highly likely to be regulated by MITF and seem to be
specific to melanoma.
Lodygin et al (2008) showed that expression of miR-34a is silenced
in a broad range of human tumours because of an aberrant CpG
methylation of the corresponding promoter region. It is interesting
to note that 43.2% of the melanoma cell lines investigated, as well as
62.5% of primary melanoma samples, showed methylation of the
miR-34a promoter, whereas the two samples of normal primary
melanocytes included in the study did not show promoter methyl-
ation. Although the tumour suppressive function of miR-34a in
melanomagenesis has still to be elucidated in detail, Migliore et al
(2008) demonstrated that a reduced expression of miR-34b, miR-34c,
and miR-199a* represents an additional pathway of regulating the
expression of the MET oncogene in melanocytic cells as well. Ectopic
expression of these miRNAs in primary melanoma cells showing a
low level of endogenous miR-34b, miR-34c, and miR-199a* led to a
decreased MET protein expression and resulted in the impairment
of MET-mediated motility in these cells.
Although not discussed in detail in this review because of space
limitations, we would like to point out that there are also two
interesting publications about miRNAs in uveal melanoma. Worley
et al (2008) depicted the potential of miRNA expression patterns
in predicting the metastatic risk of uveal melanomas, whereas Yan
et al (2009) were able to demonstrate miR-34a, a tumour suppres-
sor in uveal melanoma cells.
This summary of data shows that, up to now, only very few
miRNAs deregulated in the tumourigenesis of malignant mela-
noma have been analysed in detail and assigned at least some
melanoma-relevant target genes. Nevertheless, this limited state
of knowledge already points to a pivotal role of miRNAs in the
regulation of genes highly involved in the formation and progres-
sion of malignant melanoma.
FUTURE PROSPECTS – DIAGNOSIS AND THERAPY
Owing to the emerging, serious impact of miRNAs on tumouri-
genesis, an extensive potential of these small RNA molecules on the
development of new diagnostic tools and therapeutic approaches is
expected.
With regard to diagnostic purposes, it was shown that poorly
differentiated tumours as well can be efficiently classified by their
miRNA expression profiles (Lu et al, 2005). Expanding those
findings, Rosenfeld et al (2008) were able to construct a classifier
consisting of 48 miRNAs that is capable of determining the origin
of metastatic tumours of unknown primary origin with high
accuracy. This classifier could prove to be relevant for the
diagnosis of unknown primary melanomas that represent about
5% of all melanoma cases. Furthermore, miRNAs were demon-
strated to be surprisingly stable in serum and can thus serve as
diagnostic markers in blood samples (Mitchell et al, 2008; Gilad
et al, 2008). Unfortunately, no studies dealing with diagnostic
applications of miRNAs are available for melanoma. Here, as true
for all tumour markers for melanoma, markers distinguishing
between nevi and early melanoma, and also miRNAs separating
primary melanomas that will lead (or already led) to metastasis
from non-metastasising tumours, are urgently needed. It is impor-
tant to note that formalin-fixed and paraffin-embedded specimens
of melanocytic lesions turn out to be suitable starting material for
miRNA microarray profiling, as shown by Glud et al (2009). This
represents a crucial finding, considering the usually poor avail-
ability of fresh melanoma tissue samples.
miRNAs are also assigned large therapeutic potential, which is
founded in several aspects: (i) the possibility to utilize know-
ledge acquired during the development of siRNA therapies for
miRNA-based approaches. Large progress was achieved in the
delivery of small RNA molecules into cells for therapeutic reasons
(Whitehead et al, 2009; Love et al, 2008). Actually, Elmen et al
(2008) successfully antagonised the expression of the liver-specific
miRNA, miR-122, in African green monkeys by a simple systemic
delivery of unconjugated, PBS-formulated LNA-antimiRs. (ii) The
fact that miRNA antagonising molecules (antagomiRs/antimiRs)
and miRNA mimics (miRNA mimetics) can be used. Hence,
miRNAs upregulated as well as downregulated in malignant cells
could be targeted for therapy. (iii) The ability of miRNAs to
regulate several target genes. Thus, by targeting one miRNA, it
is likely possible to target multiple pathways involved in the
formation and/or progression of the tumour. There are already
potential therapeutic targets among the few melanoma-relevant
miRNAs analysed in detail: whereas the miR-221/-222 cluster
seems to be a promising target in more advanced melanomas,
miRNAs of the let-7 family, especially let-7a, could also be of
interest in early melanoma stages.
VNTR
miR-137
MITF
Apoptosis Dedifferentiation Proliferation Migration / invasion
Regulator
miRNA
Target gene
Cellular
function
FOXO3 c-KIT CCND1 ITGB3
miR-182
p27Kip1
miR-221/-222 let-7b let-7a
Ampl. PLZF ??
Figure 2 Overview on microRNAs (miRNAs) with validated target genes and their impact on cellular functions in malignant melanoma as summarised
in the paragraph ‘Functional characterisation of single miRNA species in melanoma cells’. The cellular functions indicated are rather related to miRNA than
to single confirmed target genes. Those miRNAs indicated by parenthesis in Figure 1 are not included in this diagram, as their target genes as well as
their pathophysiological relevance for melanoma have to still be elucidated in detail (VNTR: variable number tandem repeat; Ampl.: amplification,
PLZF: promyelocytic leukaemia zinc finger; MITF: microphthalmia-associated transcription factor; CCND1: cyclin D1; ITGB3: integrin beta 3).
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therapy
The last years of research on cancer-related miRNAs showed that
this field is complicated by several pitfalls – most importantly in
identifying target genes for particular miRNAs to unravel the
involvement of the latter in global cellular function. Two major
facts that have to be kept in mind are (i) that miRNA-mediated
regulation of gene expression can often only be found at the
protein level and (ii) that present bioinformatic algorithms are
insufficient to reliably predict related target genes. On the one
hand, this entails that cDNA array data collected over recent years
can only contribute to the identification of miRNA target genes
regulated mainly by the destabilisation of the corresponding
transcript but not of target genes regulated by inhibition of trans-
lation. Extensive progress in protein-array technology is needed
to sufficiently solve this problem. On the other hand, a lack in
understanding the fundamental rules for pairing of miRNAs to
their target sequences leads to deficiencies of current miRNA
target prediction algorithms. This point can only be challenged
by identifying and verifying several more miRNA:target gene
interactions to improve the reliability of the present algorithms.
CONCLUSION
Only few data about deregulated miRNA expression and its impact
on tumourigenesis of malignant melanoma are available up to
now. Fortunately, many groups have started to analyse miRNAs
during defined processes in melanoma development and thus new
data will be accessible in the near future. This kind of research will
help to broaden our knowledge about melanoma development by
affecting different cellular functions by targeting only one miRNA,
and will also be of importance when a therapeutic approach based
on miRNA is established. Obviously, there is a real chance of
developing new therapeutic approaches based on miRNA biology
if basic research delivers the necessary data. This is of enormous
impact, especially in the case of malignant melanoma with a
notably poor prognosis and a complete lack of effective standard
therapies.
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